Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYAMBUTOL vs ACULAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
20-30% bound to albumin.
99% bound; primary binding protein: albumin.
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
Oral: approximately 80% absorbed.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
No dosage adjustment required for renal impairment.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
No dosage adjustment required for hepatic impairment.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
Safety and efficacy in pediatric patients have not been established; use not recommended.
Consider reduced initial dose based on renal function; monitor for optic neuritis.
No specific dosage adjustment required; use same dosing as for younger adults.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
No FDA boxed warning.
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYAMBUTOL vs ACULAR, answered by our medical review team.
MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYAMBUTOL and ACULAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYAMBUTOL and ACULAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.